Overexpression of PAK is a known driver of MAPKi resistance, and constitutive activating mutations of RAC1 (RAC1P29S), an upstream effector of PAK1, are found in 10% of MAPKi progression melanoma tumors (9, 10, 16–18). Here, RAC1 is linked to melanoma.